Close
CDMO Safety Testing 2026
Novotech

Drug Research

LexaGene Approved by CDC and FDA Antibiotic Resistance Isolate Bank to Receive Samples

LexaGene Holdings, Inc, a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced that it has been recognized by the Centers for Disease Control and Prevention (CDC) and the FDA Antibiotic Resistance (AR) Isolate...

Drug-Eluting Devices: Delivering on Drug Deliveryโ€™s Combined Potential

Implantable drug-eluting devices (DEDs) have come a long way since 1938, when Finland approved a subcutaneously administered birth control device delivering levonorgestrel. Over their development history, the therapeutic performance and value of DEDs has evolved significantly, and recent innovation has...

A Powerful Pairing: Academia-Industry Collaborations for Pharmaceutical Innovation

Innovation is unarguably the essence of pharmaceutical discovery and development. Industry and academia have been working together for decades, but historically relationships did not extend far beyond the traditional exchange of funding and research. There is a risk, however,...

New state of the art cleanroom completed by WHP for ADC bio

Production of new anti-cancer drugs at ADC Bioโ€™s North Wales manufacturing plant has been boosted following completion of a new cleanroom facility, designed and built by WHP. This forms a key part of ADC Bioโ€™s construction of a new bioconjugation...

Pathogen engineered to self destruct underlies cancer vaccine platform

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-destruct once they've done their job, making it safe for use in humans. The...

Artificial DNA can control release of active ingredients from drugs

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was once a pharmacologist's dream is now much closer to...

Oncimmune and Biodesix Form Strategic Partnership to Unlock Full Potential of EarlyCDT Lung in US

Oncimmune Holdings plc ,a leading global immunodiagnostics group announces it has entered into an exclusive partnership agreement which it believes will unlock the full potential of EarlyCDT® Lung in the United States, bringing this lung cancer test to more...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป